Where is NextRNA located?

NextRNA is headquartered in Boston, United States.

Who is the current CEO of NextRNA?

Dominique Verhelle of NextRNA. They have also founded 1 company.

How many employees does NextRNA have?

As of Aug 31, 2026, the latest employee count at NextRNA is 7.

Is NextRNA a funded company?

NextRNA is a funded company, having raised a total of $56.1M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of NextRNA?

NextRNA's latest funding was a $***** Series A round on Mar 01, 2022, with participation from 7 investors. Its primary sector is Diversified Pharmaceuticals. In United States, the Diversified Pharmaceuticals sector has seen $710M in funding in 2026 to date.

Where does NextRNA rank among its competitors?

NextRNA ranks 29th amongst 70 active competitors, of which 30 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was HAYA Therapeutics, which secured $65M in May, 2025.

Who are the top competitors of NextRNA?

NextRNA's top competitors include Stoke Therapeutics, CureVac and Skyhawk Therapeutics. Among them, HAYA Therapeutics secured the most recent funding round in May, 2025.

NextRNA - 2026 Company Profile, Team, Funding & Competitors

NextRNA is a series A company based in Boston (United States), founded in 2020 by Leon Wert Lamas and Dominique Verhelle. It operates as a Developer of RNA-targeted therapeutics for multiple areas. NextRNA has raised $56.1M in funding from Cobro Ventures and Lightchain Capital. The company has 70 active competitors, including 30 funded and 12 that have exited. Its top competitors include companies like Stoke Therapeutics, CureVac and Skyhawk Therapeutics.

Company Details

Developer of RNA-targeted therapeutics for multiple areas. The company is developing therapeutics by identifying the protein responsible for the ncRNA function. The high-throughput screening platform is used to discover RNA-protein interactions and screen for molecules that disrupt the disease-related ncRNA-protein interaction.

Website: nextrnatx.com
Email ID: *****@nextrna.com
Phone Number: +1 **********

Key Metrics

Founded Year

2020

Location

Boston, United States

Stage

Series A

Total Funding

$56.1M in 2 rounds

Latest Funding Round

Series A, Mar 01, 2022, $*****

Investors

Cobro Ventures & 6 more

Ranked

29^th among 70 active competitors

Employee Count

7 as on Aug 31, 2026

Similar Companies

HAYA Therapeutics & 1 more

View NextRNA's full profile

NextRNA has raised a total funding of $56.1M over 2 rounds. Its latest funding round was a Series A round on Mar 01, 2022 for $*****. 7 investors participated in its latest round. NextRNA has 7 institutional investors.

Here is the list of recent funding rounds of NextRNA:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 01, 2022	9632639	Series A	3329334	8885348	3201527	8177588

Access funding benchmarks and valuations. Sign up today!

View details of NextRNA's funding rounds and investors

The founders of NextRNA are Leon Wert Lamas and Dominique Verhelle. Dominique Verhelle is the CEO of NextRNA.

Here are the details of NextRNA's key team members:

Leon Wert Lamas: Co-Founder of NextRNA.
Dominique Verhelle: Co-Founder & CEO of NextRNA.
Contact Info: 1 email address

View details of NextRNA's Founder profiles and Board Members

NextRNA's employee count trend

NextRNA has 7 employees as of Aug 26. Here is NextRNA's employee count trend over the years:

Uncover NextRNA's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NextRNA include Stoke Therapeutics, CureVac and Skyhawk Therapeutics. Here is the list of Top 10 competitors of NextRNA, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Stoke Therapeutics 2014, Bedford (United States), Public	Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing	$131M	RTW Investments, Apple Tree Partners & 5 others	68/100
2nd	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates & 16 others	67/100
3rd	Skyhawk Therapeutics 2017, Waltham (United States), Series B	Developer of RNA-modifying drug candidates for the treatment of multiple disorders	$181M	Alexandria, Fidelity Investments & 9 others	63/100
4th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
5th	Vico 2019, Leiden (Netherlands), Series B	Developer of RNA modulating therapies for genetic neurological diseases	$103M	Kurma Partners, Life Sciences Partners & 9 others	61/100
6th	HAYA Therapeutics 2017, Lausanne (Switzerland), Series A	Developer of RNA-based therapies for treating heart diseases	$90M	Earlybird, Humboldt Fund & 15 others	60/100
7th	WAVE Life Sciences 2012, Boston (United States), Public	RNA medicines to transform human health, treating rare and common disorders	$84M	Foresite Capital, RA Capital Management & 8 others	58/100
8th	Sarepta 1980, Cambridge (United States), Public	Developer of RNA-targeted therapeutics for the treatment of rare and infectious diseases	-	Avoro Capital, Vulcan Capital & 12 others	56/100
9th	PYC Therapeutics 2001, Nedlands (Australia), Public	Developer of the drug for retinal, liver and neuro-degenerative diseases	$30M	-	55/100
10th	Lakewood-Amedex 2006, Sarasota (United States), Public	Developer of nano RNA gene silencing platform to develop targeted therapeutics for viral infections	$36.2M	-	52/100
29th	NextRNA 2020, Boston (United States), Series A	Developer of RNA-targeted therapeutics for multiple areas	$56.1M	Willett Advisors, Rivas Capital & 5 others	34/100